Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Zevaquenabant in Healthy Volunteers
NCT04531150Phase 1Completed
- Sponsor
- Inversago
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zevaquenabant in Prader-Willi syndrome (PWS) and Nonalcoholic steatohepatitis (NASH) (5 cohorts), sponsored by Inversago. Primary endpoints: Maximum Concentration at 72 hours, Area Under the Curve at 72 hours and 1 more. Started Sep 2020; status: completed.
02
Drugs
zevaquenabant
03
Conditions
Prader-Willi syndrome (PWS)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04531150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531150.